BACKGROUND: Immunoassays for 1α,25-dihydroxyvitamin D [1α,25(OH)(2)D] lack analytical specificity. We characterized the cross-reactivity of an anti-1α,25(OH)(2)D antibody with purified vitamin D metabolites and used these data to map the chemical features of 1α,25(OH)(2)D that are important for antibody binding. Additionally, we hypothesized that when combined with isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS), antibody cross-reactivity could be used to semiselectively enrich for structurally similar metabolites of vitamin D in a multiplexed assay. METHODS: Sample preparation consisted of immunoaffinity enrichment with a solid-phase anti-1α,25(OH)(2)D antibody and derivatization. Analytes were quantified with LC-MS/MS. Supplementation and recovery studies were performed for 11 vitamin D metabolites. We developed a method for simultaneously quantifying 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3) that included deuterated internal standards for each analyte. RESULTS: The important chemical features of vitamin D metabolites for binding to the antibody were (a) native orientation of the hydroxyl group on carbon C3 in the A ring, (b) the lack of substitution at carbon C4 in the A ring, and (c) the overall polarity of the vitamin D metabolite. The multiplexed method had lower limits of quantification (20% CV) of 0.2 ng/mL, 1.0 ng/mL, 0.06 ng/mL, 3.4 pg/mL, and 2.8 pg/mL for 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3), respectively. Method comparisons to 3 other LC-MS/MS methods yielded an r(2) value >0.9, an intercept less than the lower limit of quantification, and a slope statistically indistinguishable from 1.0. CONCLUSIONS: LC-MS/MS can be used to characterize antibody cross-reactivity, a conclusion supported by our multiplexed assay for 5 vitamin D metabolites with immunoenrichment in a targeted metabolomic assay.
BACKGROUND: Immunoassays for 1α,25-dihydroxyvitamin D [1α,25(OH)(2)D] lack analytical specificity. We characterized the cross-reactivity of an anti-1α,25(OH)(2)D antibody with purified vitamin D metabolites and used these data to map the chemical features of 1α,25(OH)(2)D that are important for antibody binding. Additionally, we hypothesized that when combined with isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS), antibody cross-reactivity could be used to semiselectively enrich for structurally similar metabolites of vitamin D in a multiplexed assay. METHODS: Sample preparation consisted of immunoaffinity enrichment with a solid-phase anti-1α,25(OH)(2)D antibody and derivatization. Analytes were quantified with LC-MS/MS. Supplementation and recovery studies were performed for 11 vitamin D metabolites. We developed a method for simultaneously quantifying 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3) that included deuterated internal standards for each analyte. RESULTS: The important chemical features of vitamin D metabolites for binding to the antibody were (a) native orientation of the hydroxyl group on carbon C3 in the A ring, (b) the lack of substitution at carbon C4 in the A ring, and (c) the overall polarity of the vitamin D metabolite. The multiplexed method had lower limits of quantification (20% CV) of 0.2 ng/mL, 1.0 ng/mL, 0.06 ng/mL, 3.4 pg/mL, and 2.8 pg/mL for 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3), respectively. Method comparisons to 3 other LC-MS/MS methods yielded an r(2) value >0.9, an intercept less than the lower limit of quantification, and a slope statistically indistinguishable from 1.0. CONCLUSIONS: LC-MS/MS can be used to characterize antibody cross-reactivity, a conclusion supported by our multiplexed assay for 5 vitamin D metabolites with immunoenrichment in a targeted metabolomic assay.
Authors: M R Clements; M Davies; M E Hayes; C D Hickey; G A Lumb; E B Mawer; P H Adams Journal: Clin Endocrinol (Oxf) Date: 1992-07 Impact factor: 3.478
Authors: Jeffrey B Cheng; Michael A Levine; Norman H Bell; David J Mangelsdorf; David W Russell Journal: Proc Natl Acad Sci U S A Date: 2004-05-05 Impact factor: 11.205
Authors: Cora M Best; Eva K Pressman; Ruth Anne Queenan; Elizabeth Cooper; Françoise Vermeylen; Kimberly O O'Brien Journal: J Nutr Date: 2018-06-01 Impact factor: 4.798
Authors: Charles Ginsberg; Leila R Zelnick; Geoffrey A Block; Glenn M Chertow; Michel Chonchol; Andrew Hoofnagle; Bryan Kestenbaum; Ian H de Boer Journal: Nephrol Dial Transplant Date: 2020-04-01 Impact factor: 5.992
Authors: Aadil Kakajiwala; Thomas O Jemielita; Lawrence Copelovitch; Mary B Leonard; Susan L Furth; Amy York; Maryjane Benton; Andrew N Hoofnagle; Kimberly Windt; Karen Merrigan; April Lederman; Michelle R Denburg Journal: Pediatr Nephrol Date: 2017-06-30 Impact factor: 3.714
Authors: Casey M Rebholz; Morgan E Grams; Pamela L Lutsey; Andrew N Hoofnagle; Jeffrey R Misialek; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; Chi-Yuan Hsu; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Josef Coresh Journal: Am J Kidney Dis Date: 2015-10-23 Impact factor: 8.860
Authors: Clark M Henderson; Susan L Fink; Hanan Bassyouni; Bob Argiropoulos; Lindsay Brown; Thomas J Laha; Konner J Jackson; Raymond Lewkonia; Patrick Ferreira; Andrew N Hoofnagle; Julien L Marcadier Journal: N Engl J Med Date: 2019-03-21 Impact factor: 91.245
Authors: Clark M Henderson; Nicholas J Shulman; Brendan MacLean; Michael J MacCoss; Andrew N Hoofnagle Journal: Clin Chem Date: 2017-12-04 Impact factor: 8.327
Authors: Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard Journal: J Infect Dis Date: 2015-03-09 Impact factor: 5.226